Thiazolidinedione analogs are new antidiabetic agents that attenuate peripheral insulin resistance in noninsulin-dependent diabetic patients; however, the effects of these agents on insulin secretion are not known. We determined the short-term and long-term effects of troglitazone (CS-045) on insulin secretion in a Syrian hamster clonal ␤-cell line, HIT-T 15 cells. The direct effect of troglitazone (CS-045: 10 Ϫ6
-10
Ϫ4 M) on insulin secretion was examined in F-12 K incubation medium containing 7 mM glucose. CS-045 significantly stimulated insulin secretion within 10 min at the concentration of 10 Ϫ4 M and dose dependently stimulated insulin secretion within 60 min at the concentration of 10 T ROGLITAZONE (CS-045), one of thiazolidinedione derivatives, is a new antidiabetic agent that improves hyperglycemia by the attenuation of peripheral insulin resistance in animal models of type II diabetes mellitus and noninsulin-dependent diabetic patients (1, 2) . It has been reported that CS-045 increases glucose utilization in both muscle and liver cells in vitro (3) , antagonizes the glucoseinduced inhibition of the insulin receptor kinase, and reduces the inhibition of the insulin receptor substrate-1 phosphorylation (4). However, the exact mechanism by which CS-045 reduces peripheral insulin resistance in diabetes mellitus is not yet fully understood.
Thiazolidinedione derivatives have been reported to modify the glucose transporter (GLUT) system, especially GLUT1 and GLUT4, in both muscles and liver (3, 5) . The effect of these derivatives on peripheral insulin resistance is supposed to be mediated by the modification of peroxisome proliferator-activated receptor ␥ (PPAR␥) (6) . It is proposed that these derivatives may directly modulate cell function through the modification of the glucose transporter system or DNA binding protein such as PPAR␥ in pancreatic ␤-cells. Hyperinsulinemia, observed in noninsulin-dependent diabetic patients, is subsequently attenuated by the reduction of peripheral insulin resistance by these agents (1, 2, 5). However, CS-045 does not change plasma insulin levels in normal fed rats (7) . In contrast, an increased pancreatic insulin content and ␤-cell granulation after 12 h or 24 h of the treatment with ciglitazone, a thiazolidinedione analog, was observed in control-fed ob/ob mice. This observation suggests the possibility that ciglitazone may have an additional, perhaps a direct, action on the pancreatic islets (8) . Malaisse and Conget first demonstrated that CS-045 inhibits insulin release evoked by glucose (9) . Recently, Matsuda and his associates demonstrated that troglitazone has dual effect on insulin secretory capacity, mediated through the modulation of glucose transport activity (10) . However, the exact mechanism by which CS-045 modulates insulin secretion in pancreatic ␤-cells still remains to be determined and the long-term, direct effect of this drug has not been established.
HIT-T 15 cells, a Syrian hamster clonal ␤-cell line (11), retain glucose-stimulated insulin release (12) and responds to glucose with increased rates of insulin biosynthesis and preproinsulin messenger RNA (mRNA) levels (13, 14) . These cells allow for the study of the long-term effects of drugs on insulin secretion and ␤-cell proliferation. The present studies were undertaken to examine whether CS-045 modulates ␤-cell function in HIT-T 15 cells (11) . We investigated whether the changes in intracellular Ca 2ϩ levels may influence the effect of CS-045 on insulin secretion in HIT-T 15 cells. Finally, we determined the long-term effect of CS-045 on HIT-T 15 cell proliferation rate and insulin secretory capacity.
Materials and Methods

Cell culture
HIT-T 15 cells were purchased from Flow Laboratories, Inc. (Irvine, Scotland, UK). Cells were cultured in F-12 K medium containing 7 mm glucose and supplemented with 10% FBS (GIBCO, Grand island, NY). Cells were incubated in a 95% O 2 -5% CO 2 incubator at 37 C. For the studies on insulin secretion, cells were plated on 24-multiwell plates (5 ϫ 10 5 cells per well). On the day of the experiment, the culture medium was completely aspirated and replaced with fresh medium with the addition of CS-045, as described below.
Experimental protocols
CS-045 was kindly provided from Sankyo Company, Ltd. (Tokyo, Japan). In the first experiment, the direct effects of troglitazone (CS-045: from 10 Ϫ6 m to 10 Ϫ4 m) on insulin secretion in HIT-T 15 cells were examined by static incubation. CS-045 was dissolved in dimethyl sulfoxide (DMSO) with a final concentration of DMSO below 0.05% in the culture medium and at the same concentration among all groups to avoid the influence of increased osmolarity in insulin secretion. The range of concentrations of CS-045 used in these experiments was chosen because it has been shown to be clinically relevant in studies of peripheral insulin resistance (10 Ϫ6 m to 10 Ϫ4 m) (15) . Once confluent, the cells were washed three times with fresh medium and then incubated for 10 -60 min in 1 ml of experimental media. The medium was then aspirated and stored at Ϫ20 C for insulin assay.
In the second experiment, we determined the effect of removal of extracellular Ca 2ϩ by the addition of 1.5 mm EGTA on the 10 Ϫ4 m CS-045-induced insulin secretion. A total of 1.5 mm EGTA was added to the medium containing 7 mm glucose, 0.9 mm Ca 2ϩ . The medium was collected at 10 min following the addition of CS-045, and the aspirated medium was frozen at Ϫ20 C for assay.
In the third experiment, the cells were incubated with various concentrations of CS-045 (10 Ϫ6 m to 10 Ϫ4 m) for 1, 3, and 5 days. Following the start of the experiment, the culture medium was changed on day 2 (3-day incubation group), or on days 2 and 4 (5-day incubation group). Total insulin secretion for the final 24 h of the experiment was measured. After aspiration of the medium, cells were used for the measurement of cell proliferation rate by MTT assay, as described below.
In the fourth experiment, the cells were incubated with 10 Ϫ4 m CS-045 in the presence and absence of 50 nm nifedipine for 5 days with culture protocol similar to that of the third experiment. Insulin secretion for the last 24 h and cell proliferation rate were measured.
Measurement of cytoplasmic free Ca 2ϩ concentrations ([Ca 2ϩ ] i )
The [Ca 2ϩ ] i was measured according to the method described previously (16) . Briefly, cells were plated on round glass coverslips (diameter, 20 mm) 3 days before the experiment. Before the start of an experiment, the cells were incubated with Hanks' (Nippon Suisan Co., Tokyo, Japan) buffer containing 7 mm glucose and 4 mm Fura-2/AM (Molecular Probes, Eugene, OR) for 10 min in a dark box at room temperature. The cells were then carefully washed twice with Hanks' buffer containing 7 mm glucose without Fura-2/AM, and a slide glass was placed in a 1 ml superfusion chamber on the stage of a fluorescence microscope. A superfusion chamber was filled with 1 ml of 7 mm glucose containing Hanks' buffer without Fura-2. Fura-2 fluorescence was measured by using Model FC-300 (Mitsubishi Kasei, Inc., Tokyo, Japan), allowing fluorometry using two excitation wavelengths (340 nm and 360 nm). Photon counts were amplified every seconds. A single cell was selected and the fluorescence from a single cell was monitored before and after the addition of CS-045 (final concentration: 10 Ϫ5 m). Changes of [Ca 2ϩ ] i was expressed as the F340/F360 ratios, and the peak value after the addition of CS-045 was compared with basal value just before drug addition.
Preproinsulin mRNA expression determination by RT-PCR method
Cells were incubated with 1 ml of the F-12 K medium containing CS-045 for 24 h at 37 C. Following 24-h incubation, the medium was completely removed and cells were washed three times with fresh F-12 K medium. The cells were then sonicated in 0.8 ml of ISOGENE (Nippon Gene, Tokyo, Japan) and centrifuged at 12,000 rpm for 10 min. Total RNA was extracted from supernatants. Hamster preproinsulin mRNA and ␤-actin mRNA were measured by RT-PCR method using GeneAmp EZ rTth RNA PCR kit (Perkin Elmer, Foster City, CA). The synthetic preproinsulin primer sequences used in the present study were as follows: forward primer: 5Ј-AGCGTGGCTTCTTCTACACACC-3Ј; backward primer: 5Ј-GGTGCAGCACTGATCCACAATG-3Ј, according to the preproinsulin complementary DNA sequence obtained by Bell and Sanchez-Pescador (17) .
According to the results from our preliminary experiment confirming the linear increase of PCR products, following reverse transcription step at 60 C for 30 min, PCR was performed for 32 cycles using a 1-min denaturation step at 94 C and 1-min annealing-extension step at 60 C. An additional 7-min extension step at 60 C was added after the 32 cycles. The PCR product was loaded on an 8% acrylamide gel, and the intensity of fluorescence of the band stained by ethidium bromide was calculated using the National Institutes of Health Image 1.56 program. The relative expression of preproinsulin mRNA to ␤-actin mRNA was calculated in each sample.
Cell proliferation rate assay using MTT
Cell proliferation rate was assayed by the method of Mosmann (18) . Incubation medium was completely aspirated after the incubation with CS-045 for 1, 3, or 5 days. The MTT-formazon product was dissolved with a phosphate buffer solution. Following the addition of 10% MTT containing F-12 K medium, cells were incubated at 37 C for 4 h, the medium was aspirated, and the cells were lysed by the addition of 100 l DMSO. Ten microliters of DMSO was collected from each sample and diluted in 90 l of fresh DMSO. After mixing with a mechanical plate mixer, the optical density of each sample was measured by Kinetic Microplate-Reader (Molecular Devices Co., Menlo Park, CA) using test and reference wavelengths of 490 nm and 650 nm.
DNA fragmentation assay
According to the method previously reported (19), a Cellular DNA Fragmentation ELISA Kit (Boehringer Mannheim GmbH, Germany) was used for the determination of DNA fragmentation by CS-045. HIT-T 15 cells were incubated with 10 m BrdU overnight at 37 C, centrifuged at 250 ϫ g for 10 min adjusted to 1 ϫ 10 5 cells/ml in F-12 K medium and plated in a 96-multiwell plate. The cells were incubated with 10 Ϫ6 m to 10 Ϫ4 m CS-045 at 37 C for 72 h, and the supernatant was completely removed from each well. The cells were lysed by the addition of an incubation buffer enclosed in the kit for 30 min at room temperature. The multiplate was centrifuged at 250 ϫ g for 10 min, and the supernatant was transferred directly to the well of a multiplate precoated with anti-DNA antibody. Then, samples were incubated for 90 min at room temperature. After washing, the samples were denatured and fixed by microwave (500 W) for 5 min and frozen at Ϫ20 C for 10 min. Peroxidaseconjugated anti-BrdU solution was added and incubated for an additional 90 min at room temperature. Substrate solution was added, and it was incubated at room temperature in the dark on a plate shaker at 250 rpm for 10 min. The reaction mixture was stopped by adding 5.6% H 2 SO 4 to each well and incubating the plate for 1 min on the shaker at 250 rpm. The absorbance was measured at 450 nm (reference wavelength: 690 nm) against substrate solution as a blank.
Measurement of ␤-cell insulin content
After HIT-T 15 cells were incubated for 24 h with 10 Ϫ6 -10 Ϫ4 m CS-045 at 37 C, the supernatant was removed. The cell insulin content was measured by the method of Grodsky and Frosham (20) . The cells were solubilized in 75% acid-ethanol solution. Ten microliters of the cell extract was frozen at Ϫ20 C and used for insulin assay.
RIA
Insulin concentrations in the medium and cell extract were determined by commercially available RIA kits (Phadeceph Insulin, Pharmacia Japan, Tokyo, Japan).
Statistical analysis
All data represent mean Ϯ se. The statistical analysis of the means was performed by ANOVA, followed by Duncan's multiple range test for the individual comparisons of the means. The F340/F360 ratios were analyzed by Student's paired t test.
Results
The effect of CS-045 on insulin secretion is showing in Fig.  1 . Both the 10-min and the 60-min incubation in CS-045 caused a dose-dependent increase in insulin secretion. At the maximal concentration (10 Ϫ4 m), a 10-min incubation in CS-045 caused a significant increase in insulin secretion (Fig. 1,  left panel) . In the 60-min incubation, the effects of 10 Ϫ5 and 10 Ϫ4 m CS-045 were statistically significant. The addition of 10 Ϫ4 m CS-045 increased insulin secretion for 60 min by 182.4 Ϯ 11.9% of controls (Fig. 1, right panel) . We also examined the long-term effect of CS-045 on ␤ -cell proliferation rate and insulin secretory capacity in HIT-T 15 cells. Long-term incubation with CS-045 over 3 days significantly decreased ␤-cell proliferation rate, assessed by MTT assay (Fig. 4A) . Similarly, the incubation with CS-045 for 5 days dose dependently decreased cell proliferation rate in HIT-T 15 cells. The most pronounced effect was seen following exposure to 10 Ϫ4 m CS-045 for 5 days. However, an inhibitory effect on insulin secretion was already apparent as early as 24 h at the highest concentration of CS-045 (10 Ϫ4 m) (Fig. 4B) . At 3-day incubation, an inhibitory effect on insulin secretion was significant over 10 Ϫ5 m and at 5-day incubation, CS-045 dose dependently inhibited insulin secretion for the final 24 h.
HIT-T 15-cell insulin content significantly decreased after 24-h incubation with 10
Ϫ4 m CS-045 [control, 1058.7 Ϯ 37.6 ng/well, 10 Using ELISA, we determined changes in the amount of DNA fragmentation of HIT-T 15 cells after 3-day incubation with CS-045 (Fig. 5) 
FIG. 3. Effect of removal of extracellular Ca
2ϩ by the addition of 1.5 mM EGTA on IRI levels increased by 10 Ϫ4 M troglitazone (CS-045). The cells were incubated with CS-045 for 10 min and the supernatant was used for IRI assay. N ϭ 6 in each group. for 3 days, indicating that the addition of CS-045 may induce apoptosis after 3-day incubation. Apoptosis may contribute to the reduction of ␤-cell number caused by CS-045. Figure 6 shows the effects of 50 nm nifedipine on the reduction of ␤-cell proliferation rate, insulin secretion for 24 h, and the amount of DNA fragmentation caused by 3-day incubation with 10 Ϫ4 m CS-045. The addition of nifedipine failed to attenuate the reduction of ␤-cell proliferation rate and insulin secretion by 10 Ϫ4 m CS-045 (Fig. 6, A and B) . In contrast, the addition of nifedipine completely abolished an increase in the amount of DNA fragmentation by 10 Ϫ4 m CS-045 (Fig. 6C) .
Discussion
The present studies demonstrated that thiazolidinedione analog, CS-045, acutely stimulates insulin secretion in vitro in HIT-T 15 cells. However, insulin mRNA expression and insulin content were not increased after 24-h incubation with CS-045. These data indicated that CS-045 may stimulate the N ϭ 6 in each group. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001 vs. controls in each group.
insulin-secretory step from secretory vesicles. The addition of CS-045 immediately increased [Ca 2ϩ ] i , and its effect on insulin secretion was significantly attenuated by the removal of Ca 2ϩ from extracellular space by 1.5 mm EGTA. We have already demonstrated that another thiazolidinedione analog, pioglitazone hydrochloride (AD-4833), stimulates insulin secretion accompanied by an increase of dihydropyridine-sensitive Ca 2ϩ influx in HIT-T 15 cells (21) . Together, these findings suggest that the induction of Ca 2ϩ influx from extracellular space should be important in the stimulation of insulin secretion by thiazolidinedione derivatives.
CS-045 binds to the sulfonylurea receptor in noncompetitive manner in both clonal HIT-T 15 cells and isolated pancreatic islet cells (10) . Thiazolidinedione analogs have been reported to increase the glucose transporter expression in the peripheral tissues such as liver and muscles (3, 5) . It has been recently reported that CS-045 stimulated insulin secretion and increased glucose uptake, suggesting that glucose transport activity may be increased by CS-045 (10) . It has been demonstrated that ATP-sensitive K ϩ channel are not closed by the addition of CS-045 (10), distinct from sulfonylurea itself (22) . The present data raised the possibility that the effect of CS-045 may not be mediated only by metabolic changes such as the changes in glucose transporter system or intracellular ATP/ADP ratio, because an immediate within seconds increase in [Ca 2ϩ ]i was observed after the addition of CS-045.
From our present and previously reported observations (21), we supposed that CS-045 acts by immediately opening the voltage-dependent Ca 2ϩ channels through an unknown mechanism after binding to specific binding sites. CS-045 has been recently reported to modify the protein kinase C activity in Rat-1 fibroblasts (4). This finding raised the possibility that CS-045 may affect intracellular phosphatidyl inositide metabolism. In pancreatic ␤-cells, activation of phosphoinositide (PI) turnover increases inositol 1,4,5-triphosphate that releases Ca 2ϩ from the endoplasmic reticulum, which can trigger a peak of insulin secretion (23) . It is possible that in ␤-cells thiazolidinedione analogs may cause an increase in PI turnover leading to an increase of [Ca 2ϩ ] i , and thus resulting in the stimulation of insulin secretion in HIT-T 15 cells. In addition, recent studies reported that PPAR␥ may involve an improvement of peripheral insulin resistance by thiazolidinedione derivatives (24) . Further studies are needed to determine which intracellular mechanism should involve the stimulation of insulin secretion by CS-045, and Ca 2ϩ influx from extracellular space.
The present study uniquely demonstrated that long-term incubation with CS-045 inhibits insulin secretion and cell proliferation rate and increases the amount of DNA fragmentation, indicating the induction of apoptosis in ␤-cell. A maximal physiological concentration of CS-045 is about 10 Ϫ5 m in the serum after oral administration in clinical usage (25) . The present data raised the possibility that the continuation of higher concentration (over 10 Ϫ5 m) of CS-045 may induce ␤-cell hypofunction and cause apoptosis in pancreatic ␤-cells in vivo. Recent studies about apoptotic regulatory proteins demonstrated that bcl-2 was found in fetal islets (26) and that bcl-xL, bax, and bag-1 are expressed in adults islets (27) . It is possible that these apoptotic proteins may be involved in the apoptotic response to CS-045 in ␤-cells. Further investigations about the changes in apoptotic proteins by CS-045 are in progress now.
Nifedipine abolished the CS-045 effect on DNA fragmentation, but the addition of nifedipine failed to attenuate the reduction of cell proliferation rate and long-term insulin secretion by CS-045. These observations suggest that the mechanism by which CS-045 induces apoptosis could be different from the one by which it reduces ␤-cell proliferation rate and long-term insulin secretory capacity. Ca 2ϩ influx has been reported to induce apoptosis in rat liver (28) . It has also been shown by Juntti-Berggren et al. that an Ig M-mediated increase in the Ca 2ϩ influx into RINm5FA insulin producing cells that are blocked by a voltage-dependent L-type Ca 2ϩ channel antagonist, verapamil, contributes to pancreatic ␤-cell destruction by apoptosis (29) . In the present studies, the finding that nifedipine, a voltage-dependent L-type Ca 2ϩ channel antagonist (30) , abolished the CS-045 effect on the amount of DNA fragmentation may indicate that the induction of apoptosis by CS-045 may be in part mediated by the activation of voltage-dependent L-type Ca 2ϩ channel. In addition, it has been shown that continuous exposure to PPAR activators led to adipose conversion in 3T3-L1 preadipocytes, during which PPAR and its heterodimerization partner (retinoid X receptor) were induced and treatment of cells cultured in delipidated serum with retinoic acid caused death of the cells by apoptosis (31) . The mode of the cell death of the Reuber hepatoma cell line FaO, in which PPAR expression is highest, was characterized as apoptosis (32) . These previous observations may support a possibility that the long-term incubation with CS-045, PPAR␥ activator, may induce apoptosis in HIT-T 15 cells. However, to explain the exact mechanism of CS-045-induced reduction of cell proliferation rate, cell hypofunction, and apoptosis in pancreatic ␤-cells, further studies should be necessary.
The present data provide evidence that thiazolidinedione analog, CS-045, can acutely stimulate in vitro insulin secretion from HIT-T 15 cells. The insulin secretory action of this agent is proposed to be in part mediated by the activation of Ca 2ϩ influx through voltage-dependent Ca 2ϩ channel. In addition, this study uniquely demonstrates that long-term incubation with CS-045 inhibits ␤-cell proliferation rate in vitro and may induce apoptosis, which could cause the reduction of ␤-cell mass by CS-045.
